ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2016, Vol. 8 ›› Issue (6): 575-577.doi: 10.3969/j.issn.1674-3865.2016.06.007

• 临床研究 • 上一篇    下一篇

百蕊颗粒辅助治疗小儿肺炎支原体肺炎疗效观察

李彦彦，陈琪玮   

  1. 110032 沈阳，沈阳医学院附属第二医院儿科
  • 出版日期:2016-12-25 发布日期:2018-11-19
  • 通讯作者: 陈琪玮，E-mail：chenqw66@126.com
  • 作者简介:李彦彦(1982-)，女，主治医师。研究方向：小儿呼吸系统疾病的诊治

Efficacy analysis of Bairui particles as adjuvant therapy for children with mycoplasma pneumonia

LI Yanyan, CHEN Qiwei   

  1. Department of Pediatrics, the Second Affiliated Hospital of Shenyang Medical College, Shenyang 110032,China
  • Online:2016-12-25 Published:2018-11-19

PDF (PC)

113

摘要： 目的：观察百蕊颗粒辅助治疗小儿肺炎支原体肺炎的治疗效果。
方法：2014年7月至2015年7月沈阳医学院附属第二医院儿科收治住院的MPP患儿100例，随机分为观察组和对照组各50例。对照组在常规对症治疗的基础上予红霉素、阿奇霉素序贯治疗，观察组在对照组基础上口服百蕊颗粒。比较两组患儿临床治疗总有效率，退热时间、咳嗽消失时间及肺部啰音消失时间、不良反应发生情况。
结果：观察组治疗总有效率为94%(47/50)，显著高于对照组80%(40/50)，差异有统计意义(P<0.05)。观察组退热时间、咳嗽消失时间、肺部啰音消失时间均显著短于对照组，差异有统计学意义(P<0.05)。两组患儿的不良反应发生率相当，差异无统计学意义(P>0.05)。
结论：百蕊颗粒辅助治疗小儿肺炎支原体肺炎可显著提高临床疗效，明显改善症状体征，治疗安全有效，值得临床推广。

关键词: 肺炎支原体肺炎, 百蕊颗粒, 红霉素, 阿奇霉素, 儿童

Abstract: Objective:To observe the clinical efficacy of Bairui particles as adjuvant therapy for children with mycoplasma pneumonia.
Methods:Totally 100 children with mycoplasma pneumonia were randomly divided into an observation group(n=50) and a control group(n=50), according to the order of admission. In addition to convention therapy, erythromycin and azithromycin were also used for the control group, and Bairui particles together with the therapy for control group was used for the observation group. Compare the total effective rate, time of abatement of fever ,time for cough and lung rales to disappear and the occurrence of adverse reactions.
Results：The total effective rate of the observation group was 94%, and the control group 80%;the difference had statistical significance(P<0.05). There was significantly difference(P<0.05) on time of fever abatement, cough and lung rales between observation group and control group. The incidence of adverse drug reactions in the two groups showed no significant difference(P>0.05).
Conclusion：Bairui particles as adjuvant treatment for children with mycoplasma pneumonia can significantly promote the clinical efficacy and improve symptoms and signs, which is effective and safe and should be widely used in clinics.

Key words: Mycoplasma pneumoniae pneumonia, Bairui particles, Erythromycin, Azithromycin, Children